WO2022172085 - CELL THERAPY COMPOSITIONS AND METHODS FOR MODULATING TGF-B SIGNALING
National phase entry:
Publication Number
WO/2022/172085
Publication Date
18.08.2022
International Application No.
PCT/IB2022/000063
International Filing Date
15.02.2022
Title **
[English]
CELL THERAPY COMPOSITIONS AND METHODS FOR MODULATING TGF-B SIGNALING
[French]
COMPOSITIONS DE THÉRAPIE CELLULAIRE ET PROCÉDÉS POUR MODULER LA SIGNALISATION DU TGF-B
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
1-1, Doshomachi 4-chome
Chuo-ku, Osaka-shi
Osaka, 5410045, JP
Inventors
KUHN, Chantal
c/o Takeda Pharmaceutical Company Limited
40 Landsdowne Street
Cambridge, MA 02139, US
SHAPIRO, Gary
c/o Takeda Pharmaceutical Company Limited
40 Landsdowne Street
Cambridge, MA 02139, US
Priority Data
63/149,628
15.02.2021
US
63/306,836
04.02.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2429 | |
| EPO | Filing, Examination | 9262 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 5410 |
Total: 18297 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Methods of using polypeptides to modulate transforming growth factor-β (TGFβ) signaling (e.g., TGFβ receptors, antibodies or antigen-binding fragments thereof that specifically bind TGFβ or a TGFβ receptor) are provided. Compositions comprising the antibodies or fragments thereof and methods of using the same for treatment of diseases involving TGFβ activity are provided. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the TGFβ signaling modulators are provided herein.[French]
L'invention concerne des procédés d'utilisation de polypeptides pour moduler la signalisation du facteur de croissance transformant β (ΤGFβ) (p. ex. des récepteurs du ΤGFβ, des anticorps ou des fragments de liaison à l'antigène de ceux-ci qui se lient spécifiquement au ΤGFβ ou à un récepteur du ΤGFβ). L'invention concerne en outre des compositions comprenant les anticorps ou des fragments de ceux-ci et des procédés d'utilisation de celles-ci pour le traitement de maladies impliquant l'activité du ΤGFβ. L'invention concerne également des acides nucléiques, des vecteurs d'expression recombinés, des cellules hôtes, des fragments de liaison à l'antigène et des compositions pharmaceutiques comprenant lesdits agents de liaison à l'antigène et des fragments de ces derniers. L'invention concerne par ailleurs des procédés thérapeutiques d'utilisation des modulateurs de la signalisation du ΤGFβ.